Literature DB >> 30375559

Deep Vein Thrombosis as a Rare Presentation in a Female With Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis.

Wan Syamimee Wan Ghazali1, Nurashikin Mohammad1, Asmahan Mohd Ismail2.   

Abstract

This article aims to report a case of a young female patient with anti-neutrophil cytoplasmic antibodies-associated vasculitis complicated with pulmonary renal syndrome, multiple relapses, and who later developed venous thromboembolism. Pulmonary renal syndrome is a well- recognized and lethal complication; however, incidence of venous thromboembolism has not been well-described. In this article, we described a 38-year-old Malay female patient admitted in 2008 with three-month history of peripheral neuropathy of lower limbs and right ankle ulcers. Initial inflammatory markers were high and perinuclear Anti-Neutrophil Cytoplasmic Antibodies were positive. She was diagnosed as anti-neutrophil cytoplasmic antibodies-associated vasculitis and started on intravenous methylprednisolone with methotrexate. She presented with relapse of skin vasculitis complicated with pulmonary renal syndrome after being stable for one year. She was intubated and proceeded with plasmapheresis and hemodialysis. She completed six cycles of cyclophosphamide. Renal biopsy revealed chronic changes consistent with end stage renal disease. She further relapsed in 2011 with nasal blockage, epistaxis, and nasal deviation. Chest X-ray revealed lung nodules. Prednisolone was increased, her symptoms settled, and she was discharged with azathioprine. She was readmitted at the end of the same year due to two-day history of right deep vein thrombosis and she later succumbed to methicillin-resistant Staphylococcus aureus sepsis.

Entities:  

Keywords:  Anti-neutrophil cytoplasmic antibodies-associated vasculitis; deep vein thrombosis; pulmonary renal syndrome; venous thromboembolism

Year:  2017        PMID: 30375559      PMCID: PMC6190986          DOI: 10.5606/ArchRheumatol.2017.6108

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  9 in total

1.  Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoagulability.

Authors:  Emily von Scheven; Theresa T Lu; Helen M Emery; Melissa E Elder; Diane W Wara
Journal:  Arthritis Rheum       Date:  2003-12-15

Review 2.  Diffuse alveolar haemorrhage in ANCA-associated vasculitis.

Authors:  Stephen West; Nishkantha Arulkumaran; Phillip W Ind; Charles D Pusey
Journal:  Intern Med       Date:  2013-01-01       Impact factor: 1.271

3.  Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.

Authors:  Peter A Merkel; Grace H Lo; Janet T Holbrook; Andrea K Tibbs; Nancy B Allen; John C Davis; Gary S Hoffman; W Joseph McCune; E William St Clair; Ulrich Specks; Robert Spiera; Michelle Petri; John H Stone
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

Review 4.  ANCA vasculitis: time for a change in treatment paradigm? Not yet.

Authors:  Eleana Ntatsaki; Janice Mooney; Richard A Watts
Journal:  Rheumatology (Oxford)       Date:  2011-02-03       Impact factor: 7.580

Review 5.  Chemotherapy-induced thrombosis.

Authors:  Tufia C Haddad; Edward W Greeno
Journal:  Thromb Res       Date:  2006-01-04       Impact factor: 3.944

6.  Late onset of pANCA renal and pulmonary vasculitis in a girl affected by undifferentiated connective tissue disease.

Authors:  M G Alpigiani; A Calcagno; P Salvati; G A Rossi; G Barbano; G Ghiggeri; R Lorini
Journal:  Lupus       Date:  2010-02-04       Impact factor: 2.911

Review 7.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors.

Authors:  P M Stassen; R P H Derks; C G M Kallenberg; C A Stegeman
Journal:  Rheumatology (Oxford)       Date:  2008-04       Impact factor: 7.580

9.  Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.

Authors:  David J Bautz; Gloria A Preston; Sofia Lionaki; Peter Hewins; Alisa S Wolberg; Jia Jin Yang; Susan L Hogan; Hyunsook Chin; Stephan Moll; J Charles Jennette; Ronald J Falk
Journal:  J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 10.121

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.